Clinical trials: MDS-EB-1
Cancer, MDS-EB
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
INMB-INB16-002 is a Phase I open-label, dose escalation study of INKmune therapy in subjects with myelodysplastic syndrome (MDS) with excess blasts without Auer rods (EB-1 or 2, or CMML 1 or 2) or subjects with acute myeloid…
- Conditions
- Cancer, MDS-EB, Myelodysplastic Syndromes, Acute Myeloid Leukemia
- Trial name
- LAUREL (NCT05933070)
- Testing
- INKmune
- Where
- 3 sites in Greece, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Inmune Bio, Inc.